Home INSPIRE: A phase III study of the BLP25 liposome vaccine (L-BLP25) in Asian patients with unresectable stage III non-small cell lung cancer TITLE INSPIRE: A phase III study of the BLP25 liposome vaccine (L-BLP25) in Asian patients with unresectable stage III non-small cell lung cancer ABSTRACT The article presents a phase III study of the BLP25 liposome vaccine (L-BLP25) in unresectable stage III non-small cell lung cancer (NSCLC) patients in Asia. As stated, the study is the first large study of a therapeutic cancer vaccine for East-Asian population. It evaluates the potential of maintenance therapy with L-BLP25 to prolong survival in patients with stage III NSCLC where there are limited treatment options available. Related ArticlesVaccines for the Treatment of Non-Small Cell Lung Cancer: A Renewed Anticancer Strategy.GRIDELLI, CESARE; ROSSI, ANTONIO; MAIONE, PAOLO; FERRARA, MARIANNA LUCIANA; CASTALDO, VINCENZO; SACCO, PAOLA CLAUDIA//Oncologist;Sep2009, Vol. 14 Issue 9, p909

Carcinoma of the lung is the leading cause of cancer death worldwide, with non-small cell lung cancer (NSCLC) constituting about 85% of all new diagnoses. Standard approaches for each NSCLC stage have reached a plateau in effectiveness. A variety of novel approaches are now being investigated to...

Anemia and Limited-stage Small Cell Lung Cancer.Ershler, William B.//Clinical Oncology Alert;Sep2007, Vol. 23 Issue 9, p65

There has been much written about the importance and management of anemia in cancer patients this past year. For certain tumors, it is clear that the appearance of anemia prior to therapy confers adverse prognostic implications.1-3 One aspect of the controversy surrounding anemia is whether...

FDA Drug Approval Summary: Erlotinib (Tarceva®) Tablets.Martin H. Cohen//Oncologist;Aug2005, Vol. 10 Issue 7, p461

On November 18, 2004, erlotinib (Tarceva®; OSI Pharmaceuticals, Inc., Melville, NY, http://www.osip.com, and Genentech, Inc., South San Francisco, CA, http://www.gene.com) received regular approval as monotherapy for the treatment of patients with locally advanced or metastatic non-small cell...

Combinational Therapy Enhances the Effects of Anti-IGF-1R mAb Figitumumab to Target Small Cell Lung Cancer.Cao, Hongxin; Dong, Wei; Shen, Hongchang; Xu, Jun; Zhu, Linhai; Liu, Qi; Du, Jiajun//PLoS ONE;8/19/2015, Vol. 10 Issue 8, p1

Background: Small cell lung cancer (SCLC) is a recalcitrant malignancy with distinct biologic properties. Antibody targeting therapy has been actively investigated as a new drug modality. Methods: We tested the expression of IGF-1R and calculated the survival in 61 SCLC patients. We also...

A phase II study of amrubicin and carboplatin for previously untreated patients with extensive-disease small cell lung cancer.Ikeda, Takaya; Fukuda, Minoru; Nakamura, Yoichi; Kinoshita, Akitoshi; Senju, Hiroaki; Nakano, Hirofumi; Kitazaki, Takeshi; Ogawara, Daiki; Taniguchi, Hirokazu; Motoshima, Kohei; Yamaguchi, Hiroyuki; Nakatomi, Katsumi; Shimada, Midori; Nagashima, Seiji; Tsukamoto, Kazuhiro; Kohno, Shigeru//Cancer Chemotherapy & Pharmacology;Sep2014, Vol. 74 Issue 3, p497

Background: Amrubicin is active in the treatment of extensive-disease small cell lung cancer (ED-SCLC), and carboplatin is an analogue of cisplatin with less non-hematological toxicity. Purpose: The purpose of this study was to determine the efficacy and toxicity of amrubicin and carboplatin...

Practical management of NSCLC patients with long-term bevacizumab treatment: a report of four cases.Herder, G. J. M.; Codrington, H.; Colder, C. D.; Aerts, J. G.//Lung Cancer: Targets & Therapy;2013, Vol. 4, p55

Introduction: Previous research showed that the addition of bevacizumab (a monoclonal antibody against vascular endothelial growth factor [VEGF]) to chemotherapy resulted in a significant efficacy benefit in the treatment of selected patients with advanced nonsquamous non-small cell lung cancer...

HSP-90 inhibitor ganetespib is synergistic with doxorubicin in small cell lung cancer.Lai, C-H; Park, K-S; Lee, D-H; Alberobello, A T; Raffeld, M; Pierobon, M; Pin, E; Petricoin III, E F; Wang, Y; Giaccone, G//Oncogene;10/2/2014, Vol. 33 Issue 40, p4867

Small cell lung cancer (SCLC) at advanced stage is considered an incurable disease. Despite good response to initial chemotherapy, the responses in SCLC patients with metastatic disease are of short duration and resistance inevitably occurs. Although several target-specific drugs have altered...

Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced nonsmall- cell lung cancer (OPTIMAL, CTONG-0802).Zhou, C.; Wu, Y. L.; Chen, G.; Feng, J.; Liu, X. -Q.; Wang, C.; Zhang, S.; Wang, J.; Zhou, S.; Ren, S.; Lu, S.; Zhang, L.; Hu, C.; Luo, Y.; Chen, L.; Ye, M.; Huang, J.; Zhi, X.; Zhang, Y.; Xiu, Q.//Annals of Oncology;Sep2015, Vol. 26 Issue 9, p1877

Background: The OPTIMAL study was the first study to compare efficacy and tolerability of the epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) erlotinib, versus standard chemotherapy in first-line treatment of patients with EGFR mutation-positive advanced non-small-cell...

DKK1 is a potential novel mediator of cisplatin-refractoriness in non-small cell lung cancer cell lines.Salim, Hogir; Dali Zong; Hååg, Petra; Novak, Metka; Mörk, Birgitta; Lewensohn, Rolf; Lundholm, Lovisa; Viktorsson, Kristina; Zong, Dali//BMC Cancer;9/10/2015, Vol. 15 Issue 1, p1

Background: Platinum compounds are the mainstay of chemotherapy for lung cancer. Unfortunately treatment failure remains a critical issue since about 60 % of all non-small cell lung cancer (NSCLC) patients display intrinsic platinum resistance.Methods: We analyzed...

Courtesy of your local library

Public Libraries Near You(See All)NANJING LIBRARYLooking for a Different Library?Enter a library name or part of a name, city, state, or province.

Or enter your postal code and country to search by location: (optional)